Loading…
Employees: 462
Size Kamada (KMDA) is a United States Health Care company (Biotechnology) with a market value of $417M, the 2825th largest of 3,117 United States companies the cockpit tracks. Shares closed at $7.23 on 6 Nov 2026.
Performance Over six months the shares fell 15.4%, against -19.0% for the median peer and -1.1% for the United States market (cap-weighted) — 7th highest of 20 in its peer set.
Growth Revenue grew 11.5% over the last twelve months (peer median +13.3%); the operating margin is 14.4% (peer median -9.8%).
Valuation It trades at 15.8× forward earnings against a peer median of 27.3× (2nd cheapest of 7).
Price implies For today's price to make sense, revenue must grow about 4% a year for seven years (Req g). Recent delivered growth is +6%, so the hurdle is -2 pp: the price already allows for a slowdown.
Capital Return on invested capital runs 1.7 points above its cost of capital (9.3% WACC).
Short interest Short interest is 0.3% of the free float (15 Oct 2026).
Next results Next results expected around 9 Nov 2026 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | $204M | $195M | $164M | $145M | $123M |
| Revenue growth | — | +19% | +13% | +17% | — |
| Gross profit | $83.2M | $78.3M | $67.1M | $52.6M | $41.2M |
| EBITDA | $45.7M | $44.5M | $34.4M | $24.1M | $16.8M |
| Net income | $23.4M | $21.9M | $14.7M | $8.41M | -$2.22M |
| Free cash flow | $28.3M | $16.9M | $37.4M | -$1.56M | $23.7M |
| Capital expenditure | $10.3M | $10.7M | $10.9M | $5.94M | $3.61M |
| Total debt | $11.8M | $11.6M | $11.1M | $8.75M | $20.7M |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | KMDA | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | -7.0% | -10.9% | 7th highest of 21 |
| 6-month return | -15.4% | -19.0% | 7th highest of 20 |
| Distance from 52-week high | -22.7% | -44.7% | 3rd highest of 21 |
| Revenue growth (TTM) | +11.5% | +13.3% | 8th lowest of 18 |
| Operating margin | 14.4% | -9.8% | 6th highest of 18 |
| Forward P/E | 15.8× | 27.3× | 2nd cheapest of 7 |
| Growth the price implies (Req g, 7 yrs) | 4.1% | 5.8% | 4th least demanding of 8 |
| Growth delivered (Del g) | +6.5% | +54.0% | lowest of 7 |
| Hurdle (Req g minus delivered) | -2.4 pp | -26.9 pp | 4th least demanding of 7 |
| ROIC minus cost of capital | +1.7 pp | -7.2 pp | 6th highest of 16 |
| EV / EBITDA | 7.8× | 15.4× | 3rd cheapest of 6 |
| Net debt / EBITDA | -1.3× | -1.2× | 4th least indebted of 7 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Kamada KMDA | United States | $417M | -15% | +11% | 14% | 15.8× | 4.1% | +6.5% |
| Qyuns Therapeutics 2509.HK | Hong Kong | $415M | -17% | +230% | 56% | 10.0× | -20.2% | n/a |
| CorMedix CRMD | United States | $415M | -33% | +280% | 47% | n/a | n/a | n/a |
| Arvinas ARVN | United States | $420M | -37% | -12% | -10% | n/a | n/a | n/a |
| Beijing Kawin Technology Share-Holding 688687.SS | China | $410M | -19% | +3% | 0% | 17.0× | 43.0% | +8.9% |
| Prothena PRTA | United States | $409M | -26% | +427% | -110% | n/a | n/a | n/a |
| Polynovo PNV.AX | Australia | $426M | -12% | +13% | 5% | 89.0× | 53.3% | +37.6% |
| Edding Genor 6998.HK | Hong Kong | $408M | -45% | +1,418% | 26% | n/a | -15.8% | +197.3% |
| EirGenix 6589.TW | Taiwan | $427M | +2% | +27% | -71% | n/a | n/a | n/a |
| Hubei Goto Biopharm 300966.SZ | China | $427M | -7% | +6% | -10% | n/a | n/a | n/a |
| Altimmune ALT | United States | $405M | -33% | +55% | -320,726% | n/a | n/a | n/a |
| Ever Supreme Bio Technology 6712.TWO | Taiwan | $439M | +9% | +13% | 47% | 28.6× | 5.8% | +70.5% |
| TenNor Therapeutics Suzhou 6872.HK | Hong Kong | $440M | n/a | n/a | n/a | n/a | n/a | n/a |
| Editas Medicine EDIT | United States | $395M | -17% | +21% | -178% | n/a | n/a | n/a |
| Zura Bio ZURA | United States | $394M | -15% | n/a | n/a | n/a | n/a | n/a |
| PureTech Health PRTC.L | United Kingdom | $394M | -8% | -4% | -1,617% | n/a | n/a | n/a |
| Wuhan Hiteck Biological Pharma 300683.SZ | China | $443M | -36% | -30% | -27% | n/a | n/a | n/a |
| Shanghai Shen Lian Biomedical 688098.SS | China | $444M | -18% | -17% | -16% | n/a | n/a | n/a |
| Onconic Therapeutics 476060.KS | South Korea | $391M | -45% | +179% | 21% | n/a | 2.0% | +725.2% |
| Beijing Luzhu Biotechnology 2480.HK | Hong Kong | $390M | -33% | n/a | n/a | 26.1× | n/a | n/a |
| Qingdao Vland Biotech 603739.SS | China | $450M | -21% | +5% | 7% | 33.9× | 18.2% | +7.3% |